After their Phase 2 trial issues, the price sank like titanic. It may be the lowest price and it may be a good opportunity to go long. Analyst predictions for the company goes as high as $28.
Komentarz
⋅
[Not being 100% sure and not being a financial advisor] I think it hit the bottom. From this point on, it will most likely move up (considering all the volume going in). Any news catalyst will easily trigger the stock.
About my point about Phase 2 trial issue, any biopharma company has the risk of a failed Phase 2 trials and/or side-effects. That is why they [have to] do these trials, not immediately distribute to public. I am optimistic with the company's vision.